Allopurinol for chronic prostatitis
- PMID: 12519549
- DOI: 10.1002/14651858.CD001041
Allopurinol for chronic prostatitis
Abstract
Background: Chronic prostatitis is a condition that causes men substantial morbidity through the associated constellation of urinary symptoms, sexual dysfunction, and pelvic pain. The etiology of chronic prostatitis is unknown, and the many and varied treatments for chronic prostatitis reflect in part this knowledge gap. One novel etiologic theory is that the reflux of urine into prostatic ducts causes prostatic inflammation via high concentrations of purine and pyrimidine base-containing metabolites in prostatic secretions. This theory has led to the use of allopurinol for treatment of chronic prostatitis in hopes of lowering prostatic levels of uric acid and improving symptoms.
Objectives: To determine the effects of allopurinol in the treatment of chronic prostatitis
Search strategy: Trials were searched in computerized general and specialized databases (MEDLINE, Cochrane Library, Cochrane Prostate Group database), bibliographies of obtained articles, and direct contact with authors.
Selection criteria: All randomized trials of allopurinol versus placebo used to treat patients with chronic prostatitis. Acute prostatitis, bacterial prostatitis, and asymptomatic prostatitis were excluded. The main outcome measure was the change in patient-reported discomfort.
Data collection and analysis: The reviewers extracted the data independently for the outcomes of change in patient-reported discomfort, investigator graded prostate pain, leukocyte counts, and biochemical indices.
Main results: In this update, no new trials were identified (08/2002). Only one trial with 54 men lasting 240 days (with 330 days of follow-up) met study inclusion criteria. There was a statistically significant change favoring allopurinol in patient-reported discomfort between the study and control groups at follow-up. Between days 45-225, the mean score was -0.95 (s.d. 0.19) for the allopurinol group (7 men), compared with -0.47 (s.d. 0.21) for the placebo group (7 men). The weighted mean difference (WMD) was -0.48 (95%CI -0.690, -0.270). The mean score between days 45-135 was -1.08 (s.d. 1.29) for the 25 men in the allopurinol group, compared with -0.21 (sd 0.97) for the 14 men in the control group. The WMD was -0.87 (95%CI -1.587, -0.153). The allopurinol group had significantly less investigator graded prostate pain and had lower levels of serum urate, urine urate, and expressed prostatic secretion urate and xanthine. No significant differences between the two groups regarding leukocyte counts were found. No patient receiving allopurinol had any significant side effects. Three patients in the placebo group dropped out because of side effects.
Reviewer's conclusions: One small trial of allopurinol for treating chronic prostatitis showed improvements in patient-reported symptom improvement, investigator-graded prostate pain, and biochemical parameters. However, the data provided, the measures used, and the statistics presented do not make these findings convincing that changes in urine and prostatic secretion composition regarding purine and pyrimidine bases resulted in the relief of symptoms. Further studies of allopurinol treatment using standardized and validated outcomes measures and analyses are necessary to determine whether allopurinol is effective.
Update of
-
Allopurinol for chronic prostatitis.Cochrane Database Syst Rev. 2000;2002(2):CD001041. doi: 10.1002/14651858.CD001041. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2002;(4):CD001041. doi: 10.1002/14651858.CD001041. PMID: 10796738 Free PMC article. Updated. Review.
Similar articles
-
Allopurinol for chronic prostatitis.Cochrane Database Syst Rev. 2000;2002(2):CD001041. doi: 10.1002/14651858.CD001041. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2002;(4):CD001041. doi: 10.1002/14651858.CD001041. PMID: 10796738 Free PMC article. Updated. Review.
-
Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double-blind controlled study.J Urol. 1996 Mar;155(3):961-4. J Urol. 1996. PMID: 8583618 Clinical Trial.
-
Uricosuric medications for chronic gout.Cochrane Database Syst Rev. 2014 Nov 14;(11):CD010457. doi: 10.1002/14651858.CD010457.pub2. Cochrane Database Syst Rev. 2014. PMID: 25392987
-
Tamsulosin for benign prostatic hyperplasia.Cochrane Database Syst Rev. 2003;(1):CD002081. doi: 10.1002/14651858.CD002081. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2011 Sep 07;(9):CD002081. doi: 10.1002/14651858.CD002081.pub2. PMID: 12535426 Updated. Review.
-
Interventions for chronic abacterial prostatitis.Cochrane Database Syst Rev. 2001;1999(1):CD002080. doi: 10.1002/14651858.CD002080. Cochrane Database Syst Rev. 2001. PMID: 11279750 Free PMC article. Review.
Cited by
-
The methodological quality assessment of systematic reviews/meta-analyses of chronic prostatitis/chronic pelvic pain syndrome using AMSTAR2.BMC Med Res Methodol. 2023 Nov 27;23(1):281. doi: 10.1186/s12874-023-02095-0. BMC Med Res Methodol. 2023. PMID: 38012566 Free PMC article.
-
Conservative interventions for treating urinary incontinence in women: an Overview of Cochrane systematic reviews.Cochrane Database Syst Rev. 2022 Sep 2;9(9):CD012337. doi: 10.1002/14651858.CD012337.pub2. Cochrane Database Syst Rev. 2022. PMID: 36053030 Free PMC article. Review.
-
Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome.Cochrane Database Syst Rev. 2019 Oct 6;10(10):CD012552. doi: 10.1002/14651858.CD012552.pub2. Cochrane Database Syst Rev. 2019. PMID: 31587256 Free PMC article. Review.
-
Serum Urate, Genetic Variation, and Prostate Cancer Risk: Atherosclerosis Risk in Communities (ARIC) Study.Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1259-1261. doi: 10.1158/1055-9965.EPI-19-0161. Cancer Epidemiol Biomarkers Prev. 2019. PMID: 31263056 Free PMC article.
-
Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome.Cochrane Database Syst Rev. 2018 May 12;5(5):CD012551. doi: 10.1002/14651858.CD012551.pub3. Cochrane Database Syst Rev. 2018. PMID: 29757454 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous